Haleon PLC has been working on optimizing its capital structure, initiating a share buyback plan and rising with the support of Morgan Stanley's upgrade to its rating. Additionally, Pfizer has sold its entire stake in Haleon, which accumulated a significant value of $3.24 billion. Pfizer's disposal of its last Haleon stake led to a gain of around £2.5B. Moreover, Haleon's shares continue to rise and are lauded for their relative price strength. Despite the slow growth at the start of 2025, the company's innovation strategies cement its prominence in the market. Top managers are backing the potential of Haleon despite its somewhat mild start to 2025. Disposal of the final stake in the company signals increased independence for Haleon, making for a significant defensive play amidst the stock market sell-off. Haleon's ADR is getting closer to a key technical benchmark, indicating solid investment prospects. Following Morgan Stanley's praises, HSBC joined in downgrading Haleon's once robust stock rating.
Haleon Stocks News Analytics from Mon, 05 Aug 2024 07:00:00 GMT to Thu, 22 May 2025 07:00:00 GMT -
Rating 7
- Innovation 6
- Information 4
- Rumor -2
